Abstract
When WHO recommended offering oral pre-exposure prophylaxis (PrEP) to all people at substantial risk for HIV in 2015, PrEP was largely limited to small-scale projects and high-income settings. Since then, there has been widespread implementation of PrEP.1 However, the number of PrEP users remains small in many countries and is insufficient to impact HIV incidence. Unlike antiretroviral therapy, PrEP can be, and commonly is,2 started, stopped, and restarted, and there is growing recognition of the need to support effective use of PrEP (use during periods of risk to achieve protection against HIV).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
